New York State Common Retirement Fund Boosts Stake in LivaNova PLC (NASDAQ:LIVN)

New York State Common Retirement Fund increased its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 28.6% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 48,290 shares of the company's stock after acquiring an additional 10,733 shares during the period. New York State Common Retirement Fund owned about 0.09% of LivaNova worth $1,897,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of LIVN. UMB Bank n.a. boosted its holdings in shares of LivaNova by 340.5% in the first quarter. UMB Bank n.a. now owns 837 shares of the company's stock worth $33,000 after acquiring an additional 647 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of LivaNova by 17.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after acquiring an additional 219 shares during the period. Sterling Capital Management LLC boosted its holdings in shares of LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock worth $75,000 after acquiring an additional 1,441 shares during the period. Central Pacific Bank Trust Division boosted its holdings in shares of LivaNova by 7.0% in the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company's stock worth $173,000 after acquiring an additional 290 shares during the period. Finally, Optimize Financial Inc bought a new position in shares of LivaNova in the fourth quarter worth $208,000. Institutional investors own 97.64% of the company's stock.

LivaNova Trading Up 0.9%

NASDAQ:LIVN traded up $0.38 during mid-day trading on Friday, reaching $43.67. 411,195 shares of the company's stock traded hands, compared to its average volume of 550,516. LivaNova PLC has a 12-month low of $32.48 and a 12-month high of $57.35. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of -10.68 and a beta of 0.90. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.58 and a quick ratio of 1.37. The company has a 50 day moving average price of $44.69 and a 200-day moving average price of $43.02.

Analyst Ratings Changes

Several research firms recently issued reports on LIVN. Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a research note on Tuesday, May 20th. Wall Street Zen downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. Needham & Company LLC reiterated a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a report on Tuesday, May 13th. Barclays decreased their price objective on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a report on Thursday, May 8th. Finally, Robert W. Baird lifted their price objective on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, LivaNova currently has a consensus rating of "Buy" and an average target price of $59.29.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.